Food and Drug Administration
July 12, 2004
Briefing Information
Tazoral™ for the Treatment of Moderate to Very Severe Plaque Psoriasis Briefing Document, Allergan (PDF)
FDA Back Ground Document Regarding Oral Tazarotene for the Treatment of Moderate to Severe Psoriasis (HTM) (PDF) (Word)